|
17 Jun 2020 |
ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial
|
|
17 Jun 2020 |
Recordati: Isturisa® (osilodrostat) phase III LINC-4 trial meets its primary endpoint in Cushing’s disease
|
|
17 Jun 2020 |
Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19
|
|
17 Jun 2020 |
Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
|
|
16 Jun 2020 |
C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-Concept and to Advance Proprietary Platform
|
|
16 Jun 2020 |
Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer
|
|
16 Jun 2020 |
Addex mGlu2 PAM Program to Advance into Epilepsy Phase 2a Proof of Concept Clinical Study
|
|
16 Jun 2020 |
Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca™ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer
|
|
15 Jun 2020 |
Potent Preclinical Antitumor Activity Demonstrated by Janpix’s Selective STAT3 & STAT5 Monovalent Degraders to be presented at the Virtual Annual Meetings of the European Hematology Association and American Association for Cancer Research (Part II)
|
|
15 Jun 2020 |
Inventiva’s lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH)
|
|
15 Jun 2020 |
Dompé Presents Phase II Clinical Trial Results for Ladarixin in New-Onset Type 1 Diabetes at the American Diabetes Association's Scientific Sessions
|
|
15 Jun 2020 |
Bayer extends clinical development program for finerenone with Phase III study in patients with heart failure and preserved ejection fraction
|
|
15 Jun 2020 |
Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients
|
|
15 Jun 2020 |
Solasia Announces Positive Results of DARINAPARSIN in Pivotal Phase 2 Study for Peripheral T-Cell Lymphoma
|
|
15 Jun 2020 |
Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus
|
|
13 Jun 2020 |
Agios Announces Clinical Proof-of-Concept Has Been Established in Phase 1 Study of Mitapivat, First-in Class PKR Activator, in Sickle Cell Disease
|
|
13 Jun 2020 |
Forma Therapeutics Presents Safety, Pharmacokinetic and Pharmacodynamic Data from Phase 1 Clinical Trial for Investigational Agent FT-4202 in Patients with Sickle Cell Disease
|
|
13 Jun 2020 |
Genentech Announces 2-Year Risdiplam Data From SUNFISH and New Data From JEWELFISH in Infants, Children and Adults With Spinal Muscular Atrophy (SMA)
|
|
13 Jun 2020 |
Positive Phase III Results for Venclexta Combination in Acute Myeloid Leukemia Presented At EHA 2020
|
|
13 Jun 2020 |
Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO™ (ixazomib) in Multiple Myeloma as a First-Line Maintenance Therapy
|
|
11 Jun 2020 |
Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology
|
|
11 Jun 2020 |
Exelixis Announces Initiation of CONTACT-01 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Non-small Cell Lung Cancer
|
|
10 Jun 2020 |
Dermata Announces Positive Results from its Phase 2b Clinical Trial of Once Weekly Topical Application of DMT310 for the Treatment of Moderate to Severe Acne Vulgaris
|
|
10 Jun 2020 |
Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis
|
|
10 Jun 2020 |
Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi
|
